登录新浪财经APP 搜索【信披】查看更多考评等级 大千生态环境集团股份有限公司（以下简称"公司"）于2025年11月5日收到上海证券交易所（以下简 称"上交所"）下发的《关于大千生态环境集团股份有限公司向特定对象发行股票申请文件的审核问询 函》（上证上审（再融资）〔2025〕348号）（以下简称"审核问询函"）。 公司会同相关中介机构对审核问询函所列问题进行了认真研究和逐项落实，并按审核问询函要求对所涉 及的事项进行了资料补充和问题回复，现根据要求对审核问询函回复进行公开披露，具体内容详见公司 同日在上交所网站（www.sse.com.cn）披露的《关于大千生态环境集团股份有限公司向特定对象发行股 票申请文件的审核问询函的回复》等文件。 公司本次向特定对象发行股票事宜尚需上交所审核通过、中国证券监督管理委员会同意注册后方可实 施，最终能否通过上交所审核并获得中国证券监督管理委员会同意注册的决定及其时间尚存在不确定 性。公司将根据进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 大千生态环境集团股份有限公司董事会 证券代码：603955 证券简称：大千生态 公告编号：2025-078 大千 ...

Core Points - Daqian Ecological Environment Group Co., Ltd. has completed its response to the Shanghai Stock Exchange's inquiry regarding its application for a specific object stock issuance [1][2] - The issuance is subject to approval from the Shanghai Stock Exchange and registration by the China Securities Regulatory Commission, with uncertain timelines for approval [1][2] Group 1 - The company received an inquiry letter from the Shanghai Stock Exchange on November 5, 2025, regarding its stock issuance application [1] - The company, along with relevant intermediaries, conducted thorough research and provided supplementary materials in response to the inquiry [1] - The response to the inquiry was publicly disclosed on November 20, 2025, in accordance with regulatory requirements [1] Group 2 - The company emphasizes that the stock issuance still requires compliance with the Shanghai Stock Exchange's review process and the China Securities Regulatory Commission's registration process [2] - The final decision on whether the application will be approved and the timeline for such approval remains uncertain [2] - The company will fulfill its information disclosure obligations based on the progress of the matter [2]

Group 1 - The core point of the announcement is the change in equity holdings of major shareholders, specifically that Bio-ao Biological Group Co., Ltd. and its concerted party Tianfu Qingyuan Holdings Co., Ltd. have reduced their shareholding in Micron Biotech from 10.00% to 8.82% [1][2] - The reduction involved a total of 4,829,464 shares sold through competitive and block trading from October 23, 2025, to November 19, 2025 [2] - The equity change does not trigger a mandatory tender offer and is part of a previously disclosed share reduction plan, which is still ongoing [2][3] Group 2 - The company’s board of directors has proposed to extend the validity period of the shareholder meeting resolution regarding the issuance of A-shares to specific targets for an additional 12 months, until December 5, 2026 [5][6] - This extension is intended to ensure the smooth progress of the issuance work, with all other aspects of the issuance plan remaining unchanged [6][29] - The board meeting that approved this proposal was held on November 19, 2025, with all eight attending directors voting in favor [27][30] Group 3 - The company will hold its first temporary shareholder meeting of 2025 on December 5, 2025, at 14:30, to discuss various proposals including the extension of the A-share issuance resolution [9][39] - The meeting will utilize both on-site and online voting methods, with specific timeframes for each voting method outlined [11][12] - Shareholders must register in advance to attend the meeting, with detailed registration procedures provided [21][22]

广哈通信特别提示，本次向特定对象发行A股股票事项尚需履行深交所审核程序，并经中国证监会同意 注册后方可实施。最终能否通过深交所审核、获得中国证监会同意注册的决定及其时间均存在不确定 性。公司将根据该事项进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 登录新浪财经APP 搜索【信披】查看更多考评等级 广州广哈通信股份有限公司（证券简称：广哈通信，证券代码：300711）11月19日公告称，公司已完成 对深圳证券交易所（以下简称"深交所"）关于向特定对象发行股票申请的审核问询函回复工作，并同步 更新了募集说明书等相关申请文件。本次发行事项仍需通过深交 ...

Core Points - The company, Aotega New Energy Technology Group Co., Ltd., announced on November 20 that it has updated its supplementary documents regarding the issuance of shares to specific targets based on the Shenzhen Stock Exchange's further review opinions and the disclosure of its Q3 2025 report [1] - The application for the issuance of shares was accepted by the Shenzhen Stock Exchange on August 19, 2025, and subsequent updates were made to the financial data and other changes following the disclosure of the 2025 semi-annual report [1] - The company received a review inquiry letter from the Shenzhen Stock Exchange on September 3 and completed its response and related document revisions by September 24 [1] - The recent updates were made in light of the public disclosure of the Q3 2025 report and further review requirements from the Shenzhen Stock Exchange [1] Company Updates - The company emphasizes that the subsequent progress of the share issuance remains uncertain and will fulfill its information disclosure obligations in a timely manner based on the advancement of the matter [2] - Investors are advised to make cautious decisions and pay attention to investment risks [2]

中国经济网北京11月18日讯 盟科药业(688373.SH)昨晚披露了关于终止向特定对象发行股票事项的 公告。 公司于2025年11月15日召开第二届董事会第二十二次会议，审议通过了《关于终止向特定对象发行 股票事项的议案》。 对于终止本次向特定对象发行股票事项的原因，盟科药业表示，自公司披露本次向特定对象发行股 票事项以来，公司与海鲸药业、相关中介机构等一直在积极推进各项工作，并严格按照相关法律法规和 规范性文件要求履行了决策程序和信息披露义务。截至目前，公司主要股东GeniePharma持续反对公司 按照股东大会决议推进发行方案的执行，与公司其他股东、公司管理层之间存在较大分歧。 截至预案披露日，发行对象海鲸药业未持有公司股份，与公司、公司董事、监事及高级管理人员不 存在关联关系。本次发行完成后，发行对象海鲸药业将成为公司控股股东，本次发行构成关联交易。 盟科药业披露本次定增预案后的首个交易日，即9月23日，公司股价涨停，涨幅20.02%。 盟科药业于2022年8月5日在上交所科创板上市，公开发行股份数为13,000.00万股，发行价格为8.16 元/股，保荐机构（主承销商）中国国际金融股份有限公司，保荐 ...

Core Viewpoint - The company plans to issue A-shares to specific investors, raising up to 1.5 billion yuan, which may dilute immediate returns but includes measures to compensate for this dilution [1][6][7]. Financial Impact - The issuance is expected to increase the company's total share capital and net assets significantly, but may lead to a short-term dilution of earnings per share and return on equity [1][4][5]. - The company estimates that the issuance will involve approximately 250 million shares, based on the current total share capital of 2,031,124,274 shares [1][4]. Assumptions for Financial Projections - The analysis assumes no significant adverse changes in macroeconomic conditions, industry policies, or market situations [1][2]. - Three scenarios for 2026 net profit are considered: a 20% decrease, no change, or a 20% increase compared to 2025 [2][3]. Necessity and Rationality of the Issuance - The issuance aligns with national industrial policies and the company's strategic direction, focusing on expanding its core business in power generation and sales [7]. - The raised funds will be allocated to various wind power projects and to supplement working capital, supporting the company's main operations [7][9]. Resource Preparedness - The company has a strong personnel base with extensive experience in power generation and management, which supports its operational capabilities [8][9]. - The company possesses significant technical expertise and market knowledge, ensuring effective project implementation [8][9]. Measures to Mitigate Dilution - The company will enhance the supervision of raised funds to ensure they are used legally and effectively [10]. - It plans to expedite the construction of funded projects to realize expected benefits quickly [11]. - The company aims to improve operational efficiency and internal controls to enhance overall performance [12]. - A profit distribution system will be established to strengthen investor return mechanisms [13]. Commitments from Management - The board and senior management have committed to fulfilling the measures to mitigate dilution and protecting shareholder interests [14][15][17].

Group 1 - The core point of the article is that Ningxia Dongfang Tantalum Industry Co., Ltd. has completed its response to the Shenzhen Stock Exchange's inquiry regarding its application for a private placement of shares, and has updated its fundraising documents [1] - The company received the inquiry letter from the Shenzhen Stock Exchange on October 27, 2025, and has addressed the questions raised in the letter [1] - The issuance of shares to specific objects is subject to approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, with uncertainties regarding the approval process and timeline [1]

盟科药业表示，截至目前，公司主要股东Genie Pharma持续反对公司按照股东大会决议推进发行方案的 执行，与公司其他股东、公司管理层之间存在较大分歧。公司在近日与相关各方多次沟通后认为，持续 推进本次股票发行方案可能影响公司的稳健经营发展。为维护公司及全体股东特别是中小股东的长远利 益，公司董事会决定依据2025年第二次临时股东大会的全权授权，终止本次向特定对象发行股票事项。 北京商报讯（记者 丁宁）11月17日晚间，盟科药业（688373）发布公告称，公司于11月15日召开第二 届董事会第二十二次会议，审议通过了《关于终止向特定对象发行股票事项的议案》。 据悉，公司原拟向南京海鲸药业股份有限公司（以下简称"海鲸药业"）发行1.64亿股股份募集资金10.33 亿元。 此外，盟科药业表示，公司与海鲸药业就终止《附条件生效的向特定对象发行股份认购协议》《战略合 作协议》等相关事宜将另行协商，签订书面终止协议，妥善处理后续事宜，并根据进展情况及时履行信 息披露义务。 ...

华锐精密公告称，公司向特定对象发行股票已获必要批准与授权。2024年2月23日，公司与认购对象肖 旭凯签署《股份认购协议》。本次发行价格由45.09元/股调整为31.21元/股，发行数量为6,408,202股， 由肖旭凯全额认购。截至2025年11月11日12时，招商证券指定账户收到申购资金1.9999998442亿元，扣 除费用后，实际募资净额1.9738261819亿元。肖旭凯为公司实际控制人之一，本次发行构成关联交易， 已履行审批程序。 ...